INCYTE CORP 8-K

What Happened Incyte Corporation (INCY) filed an 8-K reporting on March 25, 2026 that it has changed titles for several senior executives effective immediately. Pablo J. Cagnoni was named President, Incyte and Global Head of Research and Development, replacing William J. Meury in the President role; Mr. Meury remains Chief Executive Officer and a member of the Board. Steven H. Stein’s title changed to Executive Vice President, Chief Medical Officer and Head of Late-stage Development, and Mohamed Issa’s title changed to Executive Vice President and Head of U.S. Commercial.

Key Details

• Effective date: March 25, 2026; 8-K filed March 26, 2026.
• New titles: Pablo J. Cagnoni — President, Incyte & Global Head of R&D; Steven H. Stein — EVP, Chief Medical Officer & Head of Late‑stage Development; Mohamed Issa — EVP & Head of U.S. Commercial.
• William J. Meury remains CEO and a board member; the title change did not involve any compensation changes for the impacted executives.
• Biographical and business experience for the impacted executives are available in Incyte’s Form 10‑K for the year ended Dec. 31, 2025 (filed Feb. 10, 2026).

Why It Matters This filing documents a leadership realignment within Incyte’s senior team that shifts operational responsibility for R&D and U.S. commercial execution while keeping CEO continuity under William Meury. For investors, the changes are notable because they clarify who will lead late‑stage development and U.S. commercialization efforts—areas that can influence clinical progress and product launches. The filing shows this is an internal reorganization (no compensation changes) rather than departures; investors should monitor future company updates for any strategic or operational actions tied to these role changes.